The discovery of pancreatitis-associated protein (PAP) [11] as a suitable biomarker for second-tier analysis from the first DBSs as well as different genetic approaches for second or third-tier testing [12,13] opened new possibilities prompting us to review the CF screening algorithm in Austria. This evidence concerns the gene REG3A and cystic fibrosis.